Global hepatitis report The World Health Organization’s (WHO) Global Hepatitis Report is a comprehensive annual report providing an overview of the global burden of hepatitis, and a detailed assessment of prevention, screening, and treatment strategies and policies. The report provides evidence-based guidance to public health practitioners, policymakers, and health care providers to inform evidence-based approaches to tackling the burden of viral hepatitis. The report states that in 2018, 325 million people globally were chronically infected with viral hepatitis (B or C), and 1.4 million people worldwide died from viral hepatitis-related liver diseases due to a lack of access to effective prevention and treatment services. More than three-quarters of those deaths occurred in low- and middle-income countries. The global burden of viral hepatitis is estimated to be more than 20 times higher in 2020. The report outlines key findings on the burden of viral hepatitis, such as: • More than a third of the population globally is unaware of their infection status • Nearly 80% of individuals living with chronic hepatitis were not accessing life-saving treatment in 2018 • More than 80% of individuals with hepatitis B and 90% of individuals with hepatitis C acquired the virus through mother-to-child transmission, unsafe medical injections, and unsafe blood transfusions • Low- and middle-income countries experience 95% of the burden of viral hepatitis deaths The WHO identifies three main strategies to reduce the burden of viral hepatitis infections: i) increasing awareness, ii) expanding coverage of prevention and treatment. iii) strengthening health systems to provide better-integrated care for virus-infected individuals. https://www.magicinepharma.com/products/hepatitis-c

https://www.magicinepharma.com/tablet/dacikast-daclatasvir

A fixed dose of ledifos tablet along with uses side effects Ledifos is a prescription medication used in the treatment of chronic hepatitis C. It is a combination of two antiviral medications: Ledipasvir and Sofosbuvir. Ledipasvir is an NS5A inhibitor, which works by blocking the virus’s ability to replicate, while Sofosbuvir is a nucleotide analogue inhibitor, which works by preventing the virus from reproducing. The combination of these medications provides a highly potent medication for the treatment of hepatitis C. Dose of its administration Ledifos is a fixed-dose combination tablet taken once daily by mouth, with or without food. The recommended dose is one tablet, taken daily for 12 weeks. For those with cirrhosis, the recommended dose is one tablet taken daily for 24 weeks. It is important to take this medication exactly as prescribed for it to be effective. A missed dose should be taken as soon as possible unless it is almost time for the next dose. If a dose is missed, it should not be doubled or taken more often than recommended. Effects to be taken with care The most common side effects associated with the use of Ledifos include headache, nausea, fatigue, and diarrhoea. Less common side effects include itching, rash, difficulty sleeping, and stomach pain. Rarely, some people may experience changes in vision, such as blurred vision or difficulty seeing colours. It is important to contact a healthcare provider immediately if any of these symptoms occur. Conclusion In addition to these side effects, some people may also experience more serious side effects while taking Ledifos. These include liver problems, depression, allergic reactions, and an increased risk of getting a viral infection. If any of these side effects occur, a healthcare provider should be consulted immediately. Also, those with a history of hepatitis B should not take Ledifos, as it can reactivate the virus. In addition, women who are pregnant or breastfeeding should not take Ledifos, as it is not known what effect it may have on the fetus or infant. FAQs 1. Ledifos tablet is mainly used in the treatment of? Ledifos is a prescription medication used in the treatment of chronic hepatitis C. 2. Ledifos tablet is a combination of which two medicines? It is a combination of two antiviral medications: Ledipasvir and Sofosbuvir. 3. Can women take a ledifos tablet? women who are pregnant or breastfeeding should not take Ledifos, as it is not known what effect it may have on the fetus or infant. https://www.magicinepharma.com/tablet/ledifos-ledipasvir-sofosbuvir